Side effects that Cause Noncompliance to Antidepressant Medications in the Course of Outpatient Treatment

Balıkçı, Adem; Uzun, Özcan; Erdem, Murat; Doruk, Ali; Cansever, Adnan; Ateş, Mehmet Alpay

doi:10.5455/bcp.20120827114140

Cited by 10 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One way to reduce the individual and societal burden of MDD is to decrease its recurrence rate. There has been some success preventing recurrence of MDD (i.e., secondary prevention) using selective serotonin reuptake inhibitors, but adults often stop taking them because of side effects (e.g., Balsikci et al, 2014). To find new targets for secondary prevention efforts, we examined the emotional architecture of individuals with current MDD and MDD in full remission using intensive longitudinal sampling.…”

Section: Discussionmentioning

confidence: 99%

Everyday Emotional Experiences in Current and Remitted Major Depressive Disorder: An Experience-Sampling Study

Thompson

Bailen

English

2021

Clinical Psychological Science

View full text Add to dashboard Cite

The emotional experiences of people with major depressive disorder (MDD) are characterized by emotional disturbances. We examined whether these patterns characterize people with MDD in remission. Participants included individuals who had experienced at least two major depressive episodes (remitted-MDD group; n = 80), had current MDD (current-MDD group; n = 48), or were control participants ( n = 87). Participants reported their momentary affect five times per day for 14 days, from which we computed the mean (i.e., intensity), standard deviation (i.e., variability), and autocorrelation (i.e., inertia). Negative affect (NA) intensity and variability, but not inertia, differed between groups; the current-MDD group had the highest levels, the control group had the lowest, and the remitted-MDD group fell in between. Differences in NA variability held after accounting for mean NA. The only significant group difference for positive affect (PA) was that PA intensity was lower in the current-MDD group compared with the other two groups. Emotional disturbances of participants with remitted MDD appear limited to NA.

show abstract

Section: Discussionmentioning

confidence: 99%

Everyday Emotional Experiences in Current and Remitted Major Depressive Disorder: An Experience-Sampling Study

Thompson

Bailen

English

2021

Clinical Psychological Science

View full text Add to dashboard Cite

show abstract

“…However, the study did not discriminate between antipsychotic and AD uses among the subjects. [ 10 ] SD can also be a source of concern, which can worsen the depressive illness, resulting in a poorer outcome. [ 7 ] Researchers stress that SD, if untreated, can have effects on the already poor quality of life, affect interpersonal relations, and negate self-esteem of patient.…”

Section: Methodsmentioning

confidence: 99%

Treatment-emergent sexual dysfunctions due to antidepressants: A primer on assessment and management strategies

Tripathi,

Agrawal,

Joshi

2024

Indian Journal of Psychiatry

View full text Add to dashboard Cite

Antidepressants (ADs) are among the most commonly prescribed drugs worldwide. Persons with mental illness taking ADs commonly report sexual dysfunction (SD) related to treatment. A brief discussion on the neurobiology of sexual functioning and mechanism of treatment-emergent SD (TESD) was performed. The incidence of prevalence of TESD in various studies has been reviewed. TESD impacts patients as it frequently leads to nonadherence, while psychiatrists have challenges in proceeding forward with treatment in such patients. Assessment of patients with suspected TESD is described with a focus on practical tips for clinicians. Five strategies (watchful waiting, drug holiday, downward titration, switching, and add-on therapy) to manage TESD have been extensively discussed with evidence in the literature. Each strategy comes with its own bag of advantages and drawbacks, which have been pointed out for simplicity. A detailed discussion on individual pharmacological strategies is given, and options for non-pharmacological management that can be tried are enlisted. Common clinical case scenarios have been discussed to incorporate the implementation of this literature.

show abstract

“…11 However, these studies are not well researched in humans. 12,13 SSRIs are among the first-line medication for MDD and since cataracts, glaucoma are the leading cause of blindness, it has become more pertinent to assess the ocular side effects of SSRIs for follow up monitoring and providing advice to patients.…”

Section: Introductionmentioning

confidence: 99%

Ocular morbidity in patients on long-term selective serotonin reuptake inhibitors (SSRIs)

Prasad¹,

Pooja

Gowda³

2022

IJOOO

View full text Add to dashboard Cite

: To assess ocular morbidity in patients on long time anti-psychotic medication- SSRI.: Cross- sectional observational study was conducted on 96 patients on anti- psychotic medication (SSRI) who attended the OPD in Department of Ophthalmology and Psychiatry, from July 2019 to July 2021. : Of 96 patients, 71(73.9%) patients had ocular morbidity. Most common ocular morbidities were dry eye 62 (87.3%) followed by, reduced corneal sensitivity 3(4.2%), cataract 3 (4.2%), glaucoma 2(2.8%), ischemic optic neuropathy 1 (1.4%). Dry eye was the most common ocular morbidity seen. SSRIs on long term usage have significant ocular side effects, which should be kept in mind by both Ophthalmologists and Psychiatrics in their clinical practise.

show abstract

Side effects that Cause Noncompliance to Antidepressant Medications in the Course of Outpatient Treatment

Cited by 10 publications

References 19 publications

Everyday Emotional Experiences in Current and Remitted Major Depressive Disorder: An Experience-Sampling Study

Everyday Emotional Experiences in Current and Remitted Major Depressive Disorder: An Experience-Sampling Study

Treatment-emergent sexual dysfunctions due to antidepressants: A primer on assessment and management strategies

Ocular morbidity in patients on long-term selective serotonin reuptake inhibitors (SSRIs)

Contact Info

Product

Resources

About